2-propioamido-5-bromopyridine | 148612-11-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-propioamido-5-bromopyridine
• 英文别名: N-(5-bromopyridin-2-yl)propionamide；2-propionamido-5-bromopyridine；N-(5-bromopyridin-2-yl)propanamide
• CAS: 148612-11-7
• 化学式: C₈H₉BrN₂O
• mdl: MFCD02630154
• 分子量: 229.076
• InChiKey: BBIDCRCDYZHCBN-UHFFFAOYSA-N

物化性质

• 沸点：
  377.9±27.0 °C(Predicted)
• 密度：
  1.543±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-propioamido-5-bromopyridine 在 甲醇 、 copper(l) iodide 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-propionamidopyridin-3-yl)ethynyl)benzamide
  参考文献：
  名称：

  Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

  摘要：

  Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML. In this study, we explored a novel series of five and six membered monocycles as alternate hinge-binding templates to replace the 6,5-fused imidazopyridazine core of ponatinib. Like ponatinib, these monocycles are tethered to pendant toluanilides via an ethynyl linker. Several compounds in this series displayed excellent in vitro potency against both native BCR-ABL and the T315I mutant. Notably, a subset of inhibitors exhibited desirable PK and were orally active in a mouse model of T315I-driven CML. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.060
• 作为产物：
  描述：

  disodium hydrogenphosphate 、 N-(pyridin-2-yl)propionamide 在 溴 作用下， 以 水 、 溶剂黄146 为溶剂， 以84.7%的产率得到2-propioamido-5-bromopyridine
  参考文献：
  名称：

  Method of producing 2-acyl amino 5-halogenopyridine compounds

  摘要：

  一种2-酰胺基吡啶通过2-酰胺基-5-卤代吡啶形成2-氨基-3-硝基-5-卤代吡啶。2-乙酰胺基-5-溴代吡啶可以通过2-酰胺基吡啶和2-酰胺基吡啶盐酸三溴化物形成。

  公开号：

  US05290943A1

文献信息

• [EN] 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 1H-PYRAZOLO[3,4-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：EPITHERIX LLC

  公开号：WO2011084486A1

  公开（公告）日：2011-07-14

  Provided herein are compounds according to Formula (I) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers.

  本文提供了按照式（I）的化合物及其药用盐，以及包含它们的组合物，用于各种方法，包括治疗结肠癌、卵巢癌、胰腺癌、乳腺癌、肝癌、前列腺癌和血液系统肿瘤。
• Synthesis of NVS-BPTF-1 and evaluation of its biological activity
  作者：Léa Mélin、Cyrus Calosing、Olesya A. Kharenko、Henrik C. Hansen、Alexandre Gagnon

  DOI：10.1016/j.bmcl.2021.128208

  日期：2021.9

  pluripotency. As part of the chromatin remodeling complex hNURF (nucleosome remodeling factor), BPTF epigenetic reader subunits are particularly important for BPTF cellular function. Here we report the synthesis of NVS-BPTF-1, a previously reported highly potent and selective BPTF-bromodomain inhibitor. Evaluation of the impact of the inhibition of BPTF-bromodomain using NVS-BPTF-1 on selected proteins involved

  BPTF（含溴结构域和 PHD 指的转录因子）是一种多结构域蛋白，在转录调控、T细胞稳态和干细胞多能性中起重要作用。作为染色质重塑复合物 hNURF（核小体重塑因子）的一部分，BPTF 表观遗传阅读器亚基对 BPTF 细胞功能尤为重要。在这里，我们报告了 NVS-BPTF-1 的合成，这是一种先前报道的高效和选择性 BPTF-溴结构域抑制剂。使用 NVS-BPTF-1 对 BPTF-溴结构域的抑制对参与抗原加工途径的选定蛋白质的影响的评估表明，仅针对 BPTF-溴结构域不足以观察到 PSMB8、PSMB9、TAP1 和 TAP2 蛋白的增加。
• Hydrogen bonding-assisted tautomerization of pyridine moieties in the coordination sphere of an Ir(i) complex
  作者：Guoyong Song、Yongxin Li、Shanshan Chen、Xingwei Li

  DOI：10.1039/b804931a

  日期：——

  Ir(I)-induced tautomerization of a pyridine moiety to a carbene in 2,3-bipyridyls has been successfully achieved where an amide group plays a key role as a hydrogen-bonding acceptor and the carbene tautomer is stabilized by both chelation effect and by hydrogen-bonding.

  成功实现了Ir(I)诱导2,3-联吡啶的吡啶结构转化为卡宾，其中酰胺基团作为氢键接受体发挥了关键作用，卡宾互变异构体则通过螯合效应和氢键的作用得以稳定。
• Mapping out the synthetic landscape for re-crystallization, co-crystallization and salt formation
  作者：Christer B. Aakeröy、Arbin Rajbanshi、Z. Jane Li、John Desper

  DOI：10.1039/c0ce00052c

  日期：——

  provide overall excellent guidelines for predicting when a salt or a co-crystal will form. The charges can also be related to the supramolecular yield of the reactions between seven derivatives of 2-aminopyridine and fifteen aromatic/aliphatic carboxylic acids. The outcome of all reactions was screened using IR spectroscopy, and twelve crystal structures were used to verify the spectroscopic assignments

  为了检查一组酸碱反应中共结晶与质子转移之间的平衡，对取代吡啶的分子静电势（MEP）表面计算与它们通过分子间相互作用与一系列羧酸进行通讯的能力相关。固态。计算出的（AM1）费用氢这些N-杂环化合物中的键键受体为预测何时形成盐或共晶提供了极好的指导。电荷还可能与以下化合物的七个衍生物之间的反应的超分子产率有关2-氨基吡啶和十五种芳族/脂肪族羧酸。使用红外光谱筛选所有反应的结果，并使用十二个晶体结构来验证光谱分配并检查主要分子间相互作用的确切性质。
• 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF
  申请人：Hood John

  公开号：US20110190290A1

  公开（公告）日：2011-08-04

  Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:

  本文提供符合I式的化合物及其药学上可接受的盐，以及包含它们的组合物，用于各种方法，包括治疗结肠癌、卵巢癌、胰腺癌、乳腺癌、肝癌、前列腺癌和血液学癌症。